TY - JOUR AU - Mezei, Gabriella AU - Batár, Péter AU - Kozma, Laura AU - Illés, Árpád AU - Kappelmayer, János AU - Bekéné Debreceni, Ildikó TI - Ponatinib Exerts an Inhibitory Effect on Collagen-induced Platelet Aggregation and Generation of Coated-Platelets JF - ANTICANCER RESEARCH J2 - ANTICANCER RES VL - 41 PY - 2021 IS - 10 SP - 4867 EP - 4874 PG - 8 SN - 0250-7005 DO - 10.21873/anticanres.15300 UR - https://m2.mtmt.hu/api/publication/32575842 ID - 32575842 AB - Background/Aim: BCR-ABL tyrosine kinase inhibitors (TKIs) are exceptionally effective drugs in the treatment of chronic myeloid leukemia, nevertheless, TKIs have also an effect on platelets. We aimed to investigate the effect of a third-generation TKI, ponatinib on platelet functions. Materials and Methods: Collagen-induced platelet aggregation and coated-platelet formation were examined using in vitro and in ex vivo samples of patients on ponatinib therapy. Results: In platelet rich plasma of healthy volunteers, ponatinib at a supra- therapeutic concentration (1,000 nM) significantly impaired collagen induced platelet aggregation (p <= 0.01) and reduced the formation of coated-platelets at 150 nM ponatinib concentration ( p <= 0.05). In addition, upon glycoprotein VI (GPVI) receptor activation, a significantly lower percentage of PAC1 binding platelets (p <= 0.05) was observed at 1,000 nM final concentration of ponatinib. Platelets, isolated from patients on ponatinib therapy showed impaired collagen elicited aggregation response, already in pre-dose samples compared to healthy donors. Conclusion: The therapeutic concentration of ponatinib impairs platelet activation processes elicited by GPVI receptor agonists. LA - English DB - MTMT ER - TY - JOUR AU - Mezei, Gabriella AU - Illés, Árpád AU - Batár, Péter TI - A krónikus myeloid leukaemia tirozin-kináz-gátló kezelésének mellékhatásai és azok gyakorlati ellátása = Practical management of side effects of tyrosine kinase inhibitor therapy in chronic myeloid leukemia JF - ORVOSI HETILAP J2 - ORV HETIL VL - 162 PY - 2021 IS - 30 SP - 1198 EP - 1207 PG - 10 SN - 0030-6002 DO - 10.1556/650.2021.32177 UR - https://m2.mtmt.hu/api/publication/32285360 ID - 32285360 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kotogány, Edit AU - Balog, József Ágoston AU - Nagy, Lajos I. AU - Alföldi, Róbert AU - Bertagnolo, Valeria AU - Brugnoli, Federica AU - Demjén, András AU - Kovács, Anita Kármen AU - Batár, Péter AU - Mezei, Gabriella AU - Szabó, Renáta AU - Kanizsai, Iván AU - Varga, Csaba AU - Puskás, László AU - Szebeni, Gábor TI - Imidazo[1,2-b]pyrazole-7-Carboxamide Derivative Induces Differentiation-Coupled Apoptosis of Immature Myeloid Cells Such as Acute Myeloid Leukemia and Myeloid-Derived Suppressor Cells JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 21 PY - 2020 IS - 14 PG - 27 SN - 1661-6596 DO - 10.3390/ijms21145135 UR - https://m2.mtmt.hu/api/publication/31385279 ID - 31385279 N1 - Laboratory of Functional Genomics, Institute of Genetics, Biological Research Centre, Temesvári krt. 62, Szeged, H6726, Hungary School in Biology, University of Szeged, Szeged, H6726, Hungary Avidin Ltd., Alsó kikötő sor 11/D, Szeged, H6726, Hungary AstridBio Technologies Ltd., Wimmer Fülöp u. 1, Szeged, H6728, Hungary Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara 70, Ferrara, 44121, Italy Department of Hematology, Faculty of Medicine, University of Debrecen, Nagyerdei körút 98, Debrecen, H4032, Hungary Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged, H6726, Hungary Export Date: 29 August 2020 Correspondence Address: Szebeni, G.J.; Laboratory of Functional Genomics, Institute of Genetics, Biological Research Centre, Avidin Ltd., Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Temesvári krt. 62, Hungary; email: szebeni.gabor@brc.hu Chemicals/CAS: amide, 17655-31-1; lactate dehydrogenase, 9001-60-9; lactate dehydrogenase A; mitogen activated protein kinase 3, 137632-07-6; stress activated protein kinase, 155215-87-5 Funding details: Magyar Tudományos Akadémia, MTA, UNKP-19-4-SZTE-36, BO/00139/17/8 Funding text 1: Funding: This research was funded by the following grants, GINOP-2.3.2-15-2016-00001 and GINOP-2.3.2-15-2016-00030 by the National Research, Development and Innovation Office, Hungary; Gábor J. Szebeni was supported by János Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00139/17/8) and by the UNKP-19-4-SZTE-36 New National Excellence Program of the Ministry for Innovation and Technology. Laboratory of Functional Genomics, Institute of Genetics, Biological Research Centre, Temesvári krt. 62, Szeged, H6726, Hungary School in Biology, University of Szeged, Szeged, H6726, Hungary Avidin Ltd., Alsó kikötő sor 11/D, Szeged, H6726, Hungary AstridBio Technologies Ltd., Wimmer Fülöp u. 1, Szeged, H6728, Hungary Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara 70, Ferrara, 44121, Italy Department of Hematology, Faculty of Medicine, University of Debrecen, Nagyerdei körút 98, Debrecen, H4032, Hungary Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged, H6726, Hungary Export Date: 10 January 2021 Correspondence Address: Szebeni, G.J.; Laboratory of Functional Genomics, Institute of Genetics, Biological Research Centre, Avidin Ltd., Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Temesvári krt. 62, Hungary; email: szebeni.gabor@brc.hu Chemicals/CAS: amide, 17655-31-1; lactate dehydrogenase, 9001-60-9; lactate dehydrogenase A; mitogen activated protein kinase 3, 137632-07-6; stress activated protein kinase, 155215-87-5 Funding details: Magyar Tudományos Akadémia, MTA, UNKP-19-4-SZTE-36, BO/00139/17/8 Funding details: Ministry for Innovation and Technology Funding details: National Research, Development and Innovation Office Funding text 1: Funding: This research was funded by the following grants, GINOP-2.3.2-15-2016-00001 and GINOP-2.3.2-15-2016-00030 by the National Research, Development and Innovation Office, Hungary; Gábor J. Szebeni was supported by János Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00139/17/8) and by the UNKP-19-4-SZTE-36 New National Excellence Program of the Ministry for Innovation and Technology. Laboratory of Functional Genomics, Institute of Genetics, Biological Research Centre, Temesvári krt. 62, Szeged, H6726, Hungary School in Biology, University of Szeged, Szeged, H6726, Hungary Avidin Ltd., Alsó kikötő sor 11/D, Szeged, H6726, Hungary AstridBio Technologies Ltd., Wimmer Fülöp u. 1, Szeged, H6728, Hungary Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara 70, Ferrara, 44121, Italy Department of Hematology, Faculty of Medicine, University of Debrecen, Nagyerdei körút 98, Debrecen, H4032, Hungary Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged, H6726, Hungary Export Date: 10 February 2021 Correspondence Address: Szebeni, G.J.; Laboratory of Functional Genomics, Temesvári krt. 62, Hungary; email: szebeni.gabor@brc.hu Correspondence Address: Szebeni, G.J.; Avidin Ltd., Alsó kikötő sor 11/D, Hungary; email: szebeni.gabor@brc.hu Correspondence Address: Szebeni, G.J.; Department of Physiology, Közép fasor 52, Hungary; email: szebeni.gabor@brc.hu Funding Agency and Grant Number: National Research, Development and Innovation Office, Hungary [GINOP-2.3.2-15-2016-00001, GINOP-2.3.2-15-2016-00030]; Janos Bolyai Research Scholarship of the Hungarian Academy of SciencesHungarian Academy of Sciences [BO/00139/17/8]; New National Excellence Program of the Ministry for Innovation and Technology [UNKP-19-4-SZTE-36] Funding text: This research was funded by the following grants, GINOP-2.3.2-15-2016-00001 and GINOP-2.3.2-15-2016-00030 by the National Research, Development and Innovation Office, Hungary; Gabor J. Szebeni was supported by Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00139/17/8) and by the UNKP-19-4-SZTE-36 New National Excellence Program of the Ministry for Innovation and Technology. Laboratory of Functional Genomics, Institute of Genetics, Biological Research Centre, Temesvári krt. 62, Szeged, H6726, Hungary School in Biology, University of Szeged, Szeged, H6726, Hungary Avidin Ltd., Alsó kikötő sor 11/D, Szeged, H6726, Hungary AstridBio Technologies Ltd., Wimmer Fülöp u. 1, Szeged, H6728, Hungary Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Via Fossato di Mortara 70, Ferrara, 44121, Italy Department of Hematology, Faculty of Medicine, University of Debrecen, Nagyerdei körút 98, Debrecen, H4032, Hungary Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged, H6726, Hungary Export Date: 12 March 2021 Correspondence Address: Szebeni, G.J.; Laboratory of Functional Genomics, Temesvári krt. 62, Hungary; email: szebeni.gabor@brc.hu Correspondence Address: Szebeni, G.J.; Avidin Ltd., Alsó kikötő sor 11/D, Hungary; email: szebeni.gabor@brc.hu Correspondence Address: Szebeni, G.J.; Department of Physiology, Közép fasor 52, Hungary; email: szebeni.gabor@brc.hu Chemicals/CAS: amide, 17655-31-1; lactate dehydrogenase, 9001-60-9; lactate dehydrogenase A; mitogen activated protein kinase 3, 137632-07-6; stress activated protein kinase, 155215-87-5 Funding details: Magyar Tudományos Akadémia, MTA, BO/00139/17/8, UNKP-19-4-SZTE-36 Funding details: Ministry for Innovation and Technology Funding details: National Research, Development and Innovation Office Funding text 1: This research was funded by the following grants, GINOP-2.3.2-15-2016-00001 and GINOP-2.3.2-15-2016-00030 by the National Research, Development and Innovation Office, Hungary; G?bor J. Szebeni was supported by J?nos Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00139/17/8) and by the UNKP-19-4-SZTE-36 New National Excellence Program of the Ministry for Innovation and Technology. Funding text 2: Funding: This research was funded by the following grants, GINOP-2.3.2-15-2016-00001 and GINOP-2.3.2-15-2016-00030 by the National Research, Development and Innovation Office, Hungary; Gábor J. Szebeni was supported by János Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00139/17/8) and by the UNKP-19-4-SZTE-36 New National Excellence Program of the Ministry for Innovation and Technology. LA - English DB - MTMT ER - TY - JOUR AU - Mezei, Gabriella AU - Bekéné Debreceni, Ildikó AU - Kerenyi, Adrienne AU - Reményi, Gyula AU - Szász, Róbert AU - Illés, Árpád AU - Kappelmayer, János AU - Batár, Péter TI - Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia JF - PLATELETS J2 - PLATELETS VL - 30 PY - 2019 IS - 7 SP - 836 EP - 843 PG - 8 SN - 0953-7104 DO - 10.1080/09537104.2018.1501470 UR - https://m2.mtmt.hu/api/publication/32005205 ID - 32005205 LA - English DB - MTMT ER - TY - JOUR AU - Bekéné Debreceni, Ildikó AU - Mezei, Gabriella AU - Batár, Péter AU - Illés, Árpád AU - Kappelmayer, János TI - Dasatinib Inhibits Procoagulant and Clot Retracting Activities of Human Platelets JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 20 PY - 2019 IS - 21 SN - 1661-6596 DO - 10.3390/ijms20215430 UR - https://m2.mtmt.hu/api/publication/31189289 ID - 31189289 LA - English DB - MTMT ER - TY - JOUR AU - Szebeni, Gábor AU - Balog, József Ágoston AU - Demjén, András AU - Alföldi, Róbert AU - Végi, Vanessza L AU - Fehér, Z. Liliána AU - Mán, Imola AU - Kotogány, Edit AU - Gubán, Barbara AU - Batár, Péter AU - Hackler, László AU - Kanizsai, Iván AU - Puskás, László TI - Imidazo[1,2-b]pyrazole-7-carboxamides Induce Apoptosis in Human Leukemia Cells at Nanomolar Concentrations. JF - MOLECULES J2 - MOLECULES VL - 23 PY - 2018 IS - 11 PG - 15 SN - 1420-3049 DO - 10.3390/molecules23112845 UR - https://m2.mtmt.hu/api/publication/30319060 ID - 30319060 N1 - Funding Agency and Grant Number: National Research, Development and Innovation Office (NKFI), Hungary [GINOP-2.3.2-15-2016-00030, GINOP-2.3.2-15-2016-00001]; UNKP-18-4 New National Excellence Program of the Ministry of Human Capacities [UNKP-18-4-SZTE-73] Funding text: This research was funded by GINOP-2.3.2-15-2016-00030 and GINOP-2.3.2-15-2016-00001 from the National Research, Development and Innovation Office (NKFI), Hungary.; GJSz was supported BY the UNKP-18-4 New National Excellence Program of the Ministry of Human Capacities (UNKP-18-4-SZTE-73). Laboratory of Functional Genomics, Biological Research Centre, Hungarian Academy of Sciences, Temesvári krt. 62, Szeged, H-6726, Hungary Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged, H-6726, Hungary Avidin Ltd., Alsó kikötő sor 11/D, Szeged, H-6726, Hungary Department of Dermatology and Allergology, University of Szeged, Korányi fasor 6, Szeged, H-6720, Hungary Department of Hematology, Institute of Internal Medicine, University of Debrecen, Nagyerdei Körút 98, Debrecen, 4032, Hungary Cited By :3 Export Date: 30 January 2020 CODEN: MOLEF Correspondence Address: Puskás, L.G.; Laboratory of Functional Genomics, Biological Research Centre, Hungarian Academy of Sciences, Temesvári krt. 62, Hungary; email: laszlo@avidinbiotech.com Laboratory of Functional Genomics, Biological Research Centre, Hungarian Academy of Sciences, Temesvári krt. 62, Szeged, H-6726, Hungary Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged, H-6726, Hungary Avidin Ltd., Alsó kikötő sor 11/D, Szeged, H-6726, Hungary Department of Dermatology and Allergology, University of Szeged, Korányi fasor 6, Szeged, H-6720, Hungary Department of Hematology, Institute of Internal Medicine, University of Debrecen, Nagyerdei Körút 98, Debrecen, 4032, Hungary Cited By :6 Export Date: 10 February 2021 CODEN: MOLEF Correspondence Address: Puskás, L.G.; Laboratory of Functional Genomics, Temesvári krt. 62, Hungary; email: laszlo@avidinbiotech.com Laboratory of Functional Genomics, Biological Research Centre, Hungarian Academy of Sciences, Temesvári krt. 62, Szeged, H-6726, Hungary Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, Szeged, H-6726, Hungary Avidin Ltd., Alsó kikötő sor 11/D, Szeged, H-6726, Hungary Department of Dermatology and Allergology, University of Szeged, Korányi fasor 6, Szeged, H-6720, Hungary Department of Hematology, Institute of Internal Medicine, University of Debrecen, Nagyerdei Körút 98, Debrecen, 4032, Hungary Cited By :6 Export Date: 19 February 2021 CODEN: MOLEF Correspondence Address: Puskás, L.G.; Laboratory of Functional Genomics, Temesvári krt. 62, Hungary; email: laszlo@avidinbiotech.com Chemicals/CAS: Antineoplastic Agents; Pyrazoles Funding details: Emberi Eroforrások Minisztériuma, EMMI, UNKP-18-4-SZTE-73 Funding details: Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, NKFIH, GINOP-2.3.2-15-2016-00001, GINOP-2.3.2-15-2016-00030 Funding details: National Research, Development and Innovation Office Funding text 1: analyzed the data, G.J.S.Funding:, A.D., L.GThis.P., Lresear.H.J.chand Iwas.K.fundedwrote thbye paper.GINOP-2.3.2-15-2016-00030 and GINOP-2.3.2-15-2016-00001 from the National Research, Development and Innovation Office (NKFI), Hungary. Funding: This research was funded by GINOP-2.3.2-15-2016-00030 and GINOP-2.3.2-15-2016-00001 from the National Research, Development and Innovation Office (NKFI), Hungary. GJSz was supported BY the UNKP-18-4 New National Excellence Program of the Ministry of Human Capacities (UNKP-18-4-SZTE-73). Funding text 2: GJSz was supported BY the UNKP-18-4 New National Excellence Program of the Ministry of Human Capacities Conflicts of Interest: Th(UeNauKtPh-o1r8s- d4-eScZlaTrEe -n7o3)c.onflict of interest. AB - Leukemia, the malignancy of the hematopoietic system accounts for 10% of cancer cases with poor overall survival rate in adults; therefore, there is a high unmet medical need for the development of novel therapeutics. Eight imidazo[1,2-b]pyrazole-7-carboxamides have been tested for cytotoxic activity against five leukemia cell lines: Acute promyelocytic leukemia (HL-60), acute monocytic leukemia (THP-1), acute T-lymphoblastic leukemia (MOLT-4), biphenotypic B myelomonocytic leukemia (MV-4-11), and erythroleukemia (K-562) cells in vitro. Imidazo[1,2-b]pyrazole-7-carboxamides hampered the viability of all five leukemia cell lines with different potential. Optimization through structure activity relationship resulted in the following IC50 values for the most effective lead compound DU385: 16.54 nM, 27.24 nM, and 32.25 nM on HL-60, MOLT-4, MV-4-11 cells, respectively. Human primary fibroblasts were much less sensitive in the applied concentration range. Both monolayer or spheroid cultures of murine 4T1 and human MCF7 breast cancer cells were less sensitive to treatment with 1.5⁻10.8 μM IC50 values. Flow cytometry confirmed the absence of necrosis and revealed 60% late apoptotic population for MV-4-11, and 50% early apoptotic population for HL-60. MOLT-4 cells showed only about 30% of total apoptotic population. Toxicogenomic study of DU385 on the most sensitive MV-4-11 cells revealed altered expression of sixteen genes as early (6 h), midterm (12 h), and late response (24 h) genes upon treatment. Changes in ALOX5AP, TXN, and SOD1 expression suggested that DU385 causes oxidative stress, which was confirmed by depletion of cellular glutathione and mitochondrial membrane depolarization induction. Imidazo[1,2-b]pyrazole-7-carboxamides reported herein induced apoptosis in human leukemia cells at nanomolar concentrations. LA - English DB - MTMT ER - TY - JOUR AU - Telek, Béla AU - Rejtő, László AU - Batár, Péter AU - Miltényi, Zsófia AU - Reményi, Gyula AU - Simon, Zsófia Zsuzsanna AU - Ujj, Zsófia Ágnes AU - Mezei, Gabriella AU - Szász, Róbert AU - Kiss, Attila AU - Udvardy, Miklós AU - Illés, Árpád TI - Az akut myeloid leukaemia gyógyszeres kezelése. Jelenlegi lehetőségek, jövőbeli kilátások JF - ORVOSI HETILAP J2 - ORV HETIL VL - 157 PY - 2016 IS - 22 SP - 843 EP - 848 PG - 6 SN - 0030-6002 DO - 10.1556/650.2016.30433 UR - https://m2.mtmt.hu/api/publication/3111420 ID - 3111420 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Selmeczi, Anna AU - Udvardy, Miklós AU - Illés, Árpád AU - Telek, Béla AU - Kiss, Attila AU - Batár, Péter AU - Reményi, Gyula AU - Szász, Róbert AU - Ujj, Zsófia Ágnes AU - Márton, Adrienn AU - Ujfalusi, Anikó AU - Hevessy Zsuzsanna, Dóra AU - Pinczés, László Imre AU - Bedekovics, Judit AU - Rejtő, László TI - Heveny myeloid leukaemiás betegeink kezelésével szerzett tapasztalataink (2007–2013) JF - ORVOSI HETILAP J2 - ORV HETIL VL - 155 PY - 2014 IS - 17 SP - 653 EP - 658 PG - 6 SN - 0030-6002 DO - 10.1556/OH.2014.29884 UR - https://m2.mtmt.hu/api/publication/2580348 ID - 2580348 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kiss, Attila AU - Reményi, Gyula AU - Szász, Róbert AU - Batár, Péter AU - Rejtő, László AU - Telek, Béla AU - Ujfalusi, Anikó AU - Oláh, Éva AU - Radványi, Gáspár AU - Udvardy, Miklós TI - Bortezomibkezelés hatásának vizsgálata myeloma multiplexes betegek autológ haemopoeticus őssejt-transzplantációja során JF - HEMATOLÓGIA-TRANSZFUZIOLÓGIA J2 - HEMATOLÓGIA-TRANSZFUZIOLÓGIA VL - 46 PY - 2013 IS - 1 SP - 23 EP - 28 PG - 6 SN - 1786-5913 UR - https://m2.mtmt.hu/api/publication/32060099 ID - 32060099 N1 - 204445 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Telek, B AU - Batár, Péter AU - Varoczy, L AU - Gergely, Lajos AU - Rejtő, László AU - Szász, Róbert AU - Miltényi, Zsófia AU - Simon, Z AU - Udvardy, Miklós AU - Illés, Árpád TI - Waldenstrom-macroglobulinaemia JF - ORVOSI HETILAP J2 - ORV HETIL VL - 154 PY - 2013 IS - 50 SP - 1970 EP - 1974 PG - 5 SN - 0030-6002 DO - 10.1556/OH.2013.29776 UR - https://m2.mtmt.hu/api/publication/2736254 ID - 2736254 AB - Waldenstrom macroglobulinemia is a rare lymphoproliferative disease of B-cell origin.These tumorous B-cells produce monoclonal IgM type protein. Diagnosis is based on the detection of lymphoplasmacytic invasion of the bone marrow and serum electrophoresis. Clinical symptoms such as anemia, hyperviscosity and neuropathy are the commom consequences of bone marrow infiltration and serum monoclonal IgM protein. Former use of alkylating agents are replaced by purine analogues, rituximab and bortezomib. Additional clinical data have also accumulated regarding autologous and allogenous stem-cell transplantation. The authors present their own clinical experience and give a detailed review of current therapeutic approaches. Orv. Hetil., 154(50), 1970-1974. LA - Hungarian DB - MTMT ER -